NeoTX's $45 million Series C to fund Phase I trial

19 February 2020

Israeli company NeoTX Therapeutics, a biotech firm with a selective t-cell redirection (STR) platform for developing targeted anticancer immunotherapies, has closed a $45 million Series C financing.

NeoTX plans to use the proceeds to advance its STR platform for the treatment of advanced and metastatic solid tumors, as well as to in-license new technologies. This latest financing takes its total fundraising beyond $60 million.

Chief executive Asher Nathan said: “With the funds raised in this financing, we intend to complete the dose escalation phase of the Phase Ib trial of naptumomab estafenatox (nap) in combination with durvalumab and continue to develop our patented STR platform.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Biotechnology